<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00812045</url>
  </required_header>
  <id_info>
    <org_study_id>D4260C00008</org_study_id>
    <nct_id>NCT00812045</nct_id>
  </id_info>
  <brief_title>Study to Assess Efficacy of AZD1236 in Patients With Cystic Fibrosis</brief_title>
  <acronym>CYBER</acronym>
  <official_title>A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase II Study to Assess the Efficacy of 28 Day Oral Administration of AZD1236 in Adult Patients With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of AZD1236 in patients with cystic
      fibrosis (CF) on inflammatory biomarkers in induced sputum, after a treatment period of 4
      weeks.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Anticipated">August 2010</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect on biomarker levels in induced sputum</measure>
    <time_frame>2 times at baseline and after 4 weeks treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Signs and symptoms (Lung function variables by spirometry, symptom scores from Diary and Health-related quality of life Questionnaire)</measure>
    <time_frame>At inclusion, at randomisation and after 4 weeks treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability (adverse events, vital signs and laboratory safety variables)</measure>
    <time_frame>throughout study (at inclusion, randomisation, after 4 weeks treatments and at follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on biomarkers in blood</measure>
    <time_frame>2 times, at baseline and after 4 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on biomarkers in urine</measure>
    <time_frame>2 times, at baseline and after 4 weeks treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1236</intervention_name>
    <description>Oral tablet, 75 mg twice daily during 4 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  Have a clinical diagnosis of cystic fibrosis with an FEV1 &gt;40% of predicted normal

          -  Be able to comply with induced sputum procedure

          -  post-menopausal surgically sterile female (total hysterectomy and /or bilateral total
             oophorectomy)

        Exclusion Criteria:

          -  Concomitant diagnosis of significant pulmonary disease other than CF-related lung
             disease, including symptomatic asthma and allergic bronchopulmonary aspergillosis

          -  Treatment with any immunomodulatory agents within 8 weeks prior to Visit 2

          -  Known to be infected with Burkholderia cepacia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew J Lockton, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D Charnwood</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shawn Aaron, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Ottawa Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ottawa</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluna</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <state>Comunidad de Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2008</study_first_submitted>
  <study_first_submitted_qc>December 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2008</study_first_posted>
  <last_update_submitted>May 5, 2009</last_update_submitted>
  <last_update_submitted_qc>May 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Andrew J Lockton, MD</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Induced sputum</keyword>
  <keyword>cystic fibrosis</keyword>
  <keyword>biomarker</keyword>
  <keyword>CYBER</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

